



an Open Access Journal by MDPI

## The Immunology of Hepatocellular Carcinoma: Towards the Future of Immunotherapy

Guest Editors:

**Dr. Valerie Chew**

Duke-NUS Medical School  
Singapore, Singapore City,  
Singapore

**Dr. Diamantis I. Tsimigras**

Department of Surgery, Division  
of Surgical Oncology, The Ohio  
State University Wexner Medical  
Center and James  
Comprehensive Cancer Center,  
395 W. 12th Ave., Columbus, OH  
43210, USA

Deadline for manuscript  
submissions:

**closed (1 March 2022)**

### Message from the Guest Editors

Dear Colleagues,

Critical information and assessment are needed to advance the research into better and more effective immunotherapeutic strategies in HCC. Hence, this Special Issue “The immunology of Hepatocellular Carcinoma: towards the future of immunotherapy” will focus on deeper understanding of the basis of immune circuits in HCC with the special focus on its immune landscapes and on the solid rationale in designing combination immunotherapy strategies with enhanced efficacy as well as tolerable and manageable irAEs.

Keywords:

- Immune microenvironment
- tumour immunology
- hepatocellular carcinoma
- immunotherapy
- chronic hepatitis infection
- cancer vaccines
- chronic liver inflammation
- non-alcoholic fatty liver disease



[mdpi.com/si/41570](https://mdpi.com/si/41570)

Dr. Valerie Chew

Dr. Diamantis I. Tsimigras

*Guest Editors*

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)